Welgus Howard G. 4

What Happened

• Howard G. Welgus, a director of Arcutis Biotherapeutics (ARQT), sold 10,000 shares in an open-market transaction on April 1, 2026. The weighted average sale price was $23.88 per share, for total proceeds of approximately $238,801. This was a sale (not a purchase), and it was executed under a previously adopted trading plan.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (appears timely; Form 4s are due within two business days of the transaction).
• Price: weighted average $23.88; individual sale prices ranged from $23.61 to $24.12.
• Total shares sold: 10,000; total proceeds ≈ $238,801.
• Shares owned after transaction: not disclosed in the information provided in your summary.
• Notable footnotes:
  • The sale was made pursuant to a 10b5-1 trading plan adopted March 11, 2025, with a plan end date of May 29, 2026.
  • The filing notes the reported price is a weighted average and offers to provide a breakdown of the number of shares sold at each price in the $23.61–$24.12 range upon request.

Context

• Sales executed under 10b5-1 plans are prearranged and are generally considered routine rather than a direct signal of the insider’s short-term view on the company. This filing reports a straightforward open-market sale; there is no indication of option exercise, gift, or tax withholding tied to this transaction.